Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV
NCT ID: NCT04431375
Last Updated: 2022-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
70 participants
INTERVENTIONAL
2020-06-22
2022-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study the patients who meet the inclusion criteria will be randomized to either receive Tenofovir or with FMT + plasma exchange along with Tenofovir . Blood samples \& stool samples will be taken \& analysis will be done accordingly .The patients are followed for 90 days MELD,APACHE \& SOFA scores are calculated.Then statistical analysis will be done to find whether the addition of plasma exchange \& FMT adds benefit compared to tenofovir treatment alone .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.
NCT02689245
Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure
NCT01074645
The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Failure
NCT03640728
Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B
NCT04629976
A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)
NCT01727271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study the patients who meet the inclusion criteria will be randomized to either receive Tenofovir or with FMT + plasma exchange along with Tenofovir . Blood samples \& stool samples will be taken \& analysis will be done accordingly .The patients are followed for 90 days MELD,APACHE \& SOFA scores are calculated.Then statistical analysis will be done to find whether the addition of plasma exchange \& FMT adds benefit compared to tenofovir treatment alone .
Study period: 2 Years
Intervention:
The patients in Group A will receive T.Tenofovir \[antiviral\] 300mg per oral once a day .
The patients in Group B will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
Intravenous antibiotics will be given to all patients included in study empirically, because of high risk of infection in these patients. Patients with sepsis are excluded from the study.
Methodology for FMT - Fresh Stool \[30 g\] is obtained from donor \<3 hr before FMT. 150 mL sterile 0.9N saline is added to sample \& homogenized in a blender. It is Continued 3 times in pulses of 20-30 secs, till homogenous suspension. Slow filtration is done with membrane filter (330µm) to give adequate time. Filtration is repeated 3 times. Patient is kept NPO for 4 hrs. prior to the instillation .100 ml of fresh filtrate is given for 7 days through naso-jejunal tube over 5-10 minutes .Patient is kept reclined at 45° for 4 hr. Normal diet is given after 2 hr of procedure. IV antibiotics are continued as per institutional protocol in case of sepsis.
Methodology for plasma exchange \[PE\] - Circulatory access will be established through a double lumen catheter via the patient's femoral vein. The total exchanged plasma volume will be 2500-3500 mL, and the Plasma Exchange rate will be 20-25 mL/min. Fresh-frozen plasma (FFP) will be supplied by the ILBS Blood Bank. Dexamethasone (5 mg) and heparin (2500 U) will be injected routinely before PE. Heparin will be neutralized at the end of PE by an injection of 20-50 mg protamine sulfate. PE will be repeated alternate day for a total of 2 sessions Adverse effects: FMT FMT - Sore throat and difficulty in deglutition secondary to naso-gastric tube insertion Plasma exchange PE
* Hypocalcemia
* Hypokalemia
* Metabolic alkalosis
* Hypotension
* Anaphylaxis
* TRALI TENOFOVIR Tenofovir
* Reversible proximal renal tubular toxicity.
* Reduced bone mineral density
* Manifestations of mitochondrial toxicity (i.e., neuropathy, myopathy, lactic acidosis
Stopping rule of study:
* Allergic reactions except mild drug reactions
* Arterial hypotension or development of shock /Hypertension
* Arrhythmias
* Development or progression of organ failures during therapy
* Transfusion related lung injury
* Uncontrolled Bleeding or DIC
* Severe dyselectrolytemia( k+\<2.5 or \>5.5)
* Seizures/tetany
* Patients who are undergoing or listed for Transplantation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
plasma Exchange+Tenofovir+FMT
Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
Plasma Exchange
Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
Tenofovir
Tenofovir \[antiviral\] 300mg PO once a day .
Fecal Mircobiota Transplantation
FMT for 7 days
Tenofovir
TabletTenofovir \[antiviral\] 300mg per oral once a day
Tenofovir
Tenofovir \[antiviral\] 300mg PO once a day .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma Exchange
Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
Tenofovir
Tenofovir \[antiviral\] 300mg PO once a day .
Fecal Mircobiota Transplantation
FMT for 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with ACLF - HBV reactivation according to APASL guidelines.
* MELD \< 30 WITH AKI,HE
* MELD \< 30 WITH OUT EXTRAHEPATIC FAILURE
Exclusion Criteria
* Co existing hepatitis A,E,D
* HCC
* Sepsis
* Alcohol intake, substance abuse, HIV, IBD, chronic constipation or diarrhoea
* Allergy to plasma, protamine or heparin,
* Active hemorrhage or disseminated intravascular coagulation (DIC)
* Unstable hemodynamics (e.g., blood pressure \<90/60 mmHg, heart rate \>100 bpm),
* Cerebral or myocardiac infarction
* Pregnancy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-ACLF-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.